Exciting Advances in Gut Health from EnteroBiotix
EnteroBiotix Limited, a pioneering biopharmaceutical company focused on developing innovative therapies for gut health, has made a significant announcement regarding its Phase 2a TrIuMPH clinical trial data for EBX-102-02. This trial, which involved 122 adults suffering from irritable bowel syndrome with constipation (IBS-C), has been selected for a prestigious late-breaking oral presentation at an upcoming event that gathers the top minds in digestive health.
Details of the Late-Breaking Presentation
The presentation, titled "A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product, in patients with irritable bowel syndrome with constipation; the TrIuMPH trial," will be showcased by Professor Anthony Hobson. It is set to take place on 06 May at the DDW Clinical Science Late-Breaking Abstract Plenary session, conveniently located in Room 6A. Attendees can look forward to learning about the significant advancements and results achieved in this clinical trial. The abstract has been assigned the number 987b and will be under embargo until the session time.
Who is EnteroBiotix?
EnteroBiotix is not just any biotechnology firm; it holds a crucial position within the clinical-stage sector. The company is dedicated to developing microbiome-based treatments specifically targeted at conditions like IBS and other related gastrointestinal disorders. With its proprietary technology platform, EnteroBiotix is paving the way for next-generation therapies that aim to restore gut microbiome function, presenting options that can truly make a difference for individuals suffering from these conditions.
Innovations and Technologies
At the heart of EnteroBiotix's offerings is EBX-102-02, a full-spectrum microbiome therapeutic. This product stands out due to its high-diversity consortium of gut-derived microbes, all produced with the help of their proprietary AMPLA™ technology. Designed as an off-white, odourless powder that comes in easy-to-swallow capsules, EBX-102-02 exhibits a robust stability profile, offering a promising solution for individuals with gut microbiome dysfunction, and specifically targeting IBS symptoms.
Moving Forward with Confidence
As EnteroBiotix prepares to share its latest research with the world, the emphasis remains on improving the quality of life for patients through effective microbiome therapies. The independent control the company maintains over its supply chain, thanks to its MHRA licensed manufacturing capabilities and donor program, assures that they can consistently deliver high-quality products to patients needing them.
Contact Information for Further Inquiries
For anyone interested in learning more about EnteroBiotix or seeking further details regarding the Phase 2a trial results, Dr. James McIlroy, CEO of EnteroBiotix, is the point of contact. He can be reached via email at info@enterobiotix.com. Additionally, inquiries can also be sent to the communications team at ICR Healthcare, where Namrata Taak and Kris Lam will be available to assist. Their email contact is enterobiotix@ICRHealthcare.com.
Frequently Asked Questions
What is EnteroBiotix known for?
EnteroBiotix is recognized for developing microbiome-based therapeutics aimed at gut health, particularly for conditions like IBS.
What are the results being presented?
The company will present data from its Phase 2a TrIuMPH trial regarding the safety and efficacy of EBX-102-02 for IBS-C patients.
When will the presentation take place?
The presentation is scheduled for 06 May at the Digestive Disease Week event.
Who is the presenter for the presentation?
Professor Anthony Hobson will present the key findings of the trial.
How can I contact EnteroBiotix?
For inquiries, contact Dr. James McIlroy at info@enterobiotix.com or the ICR team at enterobiotix@ICRHealthcare.com.